首页> 外文期刊>FEBS Open Bio >Silencing of FABP1 ameliorates hepatic steatosis, inflammation, and oxidative stress in mice with nonalcoholic fatty liver disease
【24h】

Silencing of FABP1 ameliorates hepatic steatosis, inflammation, and oxidative stress in mice with nonalcoholic fatty liver disease

机译:沉默FABP1可改善非酒精性脂肪肝疾病小鼠的肝脂肪变性,炎症和氧化应激

获取原文
           

摘要

Nonalcoholic fatty liver disease (NAFLD) is increasing in prevalence worldwide and has been identified as a risk factor for cirrhosis and hepatocellular carcinoma. However, there is no effective pharmacologic treatment for NAFLD. FABP1 is a liver‐specific fatty acid‐binding protein (FABP) that plays important roles in intracellular lipid metabolism in the liver. We investigated the effect of repression of FABP1 expression on NAFLD, using adenovirus‐mediated silencing of FABP1. FABP1 knockdown in the liver decreased the liver weight and hepatic triglyceride (TG) accumulation. The expression of inflammatory and oxidative stress markers in the liver was also reduced. The level of thiobarbituric acid‐reactive substances, a marker of lipid peroxidation, in the liver of FABP1 knockdown mice was significantly decreased. These results suggest that FABP1 reduction in the liver is an effective approach against NAFLD.
机译:非酒精性脂肪肝疾病(NAFLD)在世界范围内的发病率正在增加,并且已被确定为肝硬化和肝细胞癌的危险因素。但是,目前尚无有效的NAFLD药物治疗方法。 FABP1是一种肝脏特异性脂肪酸结合蛋白(FABP),在肝脏细胞内脂质代谢中起重要作用。我们使用腺病毒介导的FABP1沉默研究了FABP1表达对NAFLD的抑制作用。肝脏中FABP1的敲低降低了肝脏的重量和肝甘油三酸酯(TG)的积累。肝脏中炎症和氧化应激标志物的表达也降低了。 FABP1敲低小鼠肝脏中的硫代巴比妥酸反应性物质(脂质过氧化的标志物)的水平显着降低。这些结果表明,减少肝脏中FABP1是抗NAFLD的有效方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号